Amicus Therapeutics Inc. (FOLD)
NASDAQ: FOLD
· Real-Time Price · USD
6.00
-0.08 (-1.32%)
At close: May 09, 2025, 3:59 PM
6.10
1.67%
After-hours: May 09, 2025, 04:59 PM EDT
-1.32% (1D)
| Bid | 5.9 |
| Market Cap | 1.85B |
| Revenue (ttm) | 543.14M |
| Net Income (ttm) | -29.37M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -66.67 |
| Forward PE | 18.47 |
| Analyst | Buy |
| Ask | 6.5 |
| Volume | 7,216,237 |
| Avg. Volume (20D) | 3,485,716 |
| Open | 6.09 |
| Previous Close | 6.08 |
| Day's Range | 5.97 - 6.24 |
| 52-Week Range | 5.93 - 12.65 |
| Beta | 0.64 |
About FOLD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FOLD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FOLD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEarnings Surprise
Amicus Therapeutics has released their quartely earnings
on May 1, 2025:
1 week ago
-13.02%
Amicus Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
6 months ago
+14%
Amicus Therapeutics shares are trading higher after the company announced it entered into a license agreement with Teva and resolved its Galafold patent litigation.
1 month ago · seekingalpha.com
Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving...
